Skip to content

Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer

Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03915171
Enrollment
50
Registered
2019-04-16
Start date
2019-03-01
Completion date
2020-06-01
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer

Keywords

NGS bMSI Gastrointestinal

Brief summary

To study the sensitivity and specificity of NGS in detecting Microsatellite State in blood and to evaluate its potential application in gastrointestinal cancer.

Detailed description

NGS can not only detect tissue samples, but also blood samples. For some inoperable cancer patients, the acquisition of tissue samples is difficult and traumatic. It is of great significance for the diagnosis and treatment of these patients to determine MSI status by blood testing. In addition, the heterogeneity of malignant tumors is usually strong, blood testing can overcome the heterogeneity of tissue, and can dynamically monitor the patient's condition. 50 patients with gastric cancer, duodenal cancer and small intestinal cancer will be enrolled in the study. Among them, 30 patients with MSI-H and 20 patients with MSS confirmed by IHC/PCR.The investigators will use 520 gene panel for NGS sequencing of tissue and blood samples from selected patients to study the sensitivity and specificity of NGS in detecting Microsatellite State in blood.

Interventions

DIAGNOSTIC_TESTNext generation sequencing

NGS can provide genetic and MSI test for patients

Sponsors

China Medical University, China
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age (\>18 years old). * Histologically diagnosed as gastric cancer, duodenal cancer or small intestinal cancer (stage III, stage IV). * The status of dMMR/pMMR was confirmed by IHC/PCR. * with tissue and blood samples (including ctDNA and white blood cells) that meet the requirements. * Agree to provide demographic, medical history, pathological diagnosis, imaging diagnosis, TNM staging, ECOG score and other information.

Exclusion criteria

* Suffering from other malignant tumors at the same time. * Others that the investigator consider that is inappropriate for this study.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of blood MSI detected by NGS1 yearTo study the sensitivity and specificity of blood MSI detected by NGS.

Secondary

MeasureTime frameDescription
Ideal sequencing depth of MSI in blood test1 yearTo study the ideal sequencing depth of MSI in blood test.
Correlation between MSI status and TMB1 yearTo study the correlation between MSI status and TMB.
Correlation between MMR gene and other gene mutations1 yearTo study thecorrelation between MMR gene and other gene mutations.

Countries

China

Contacts

Primary ContactYunpeng Liu, ph.D
cmuliuyunpeng@hotmail.com+86(0)24 961200
Backup ContactXiujuan Qu
qu_xiujuan@hotmail.com+86(0)24 83282542

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026